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Abstract
TCF3-HLF-fusion positive acute lymphoblastic leukemia (ALL) is currently incurable. Employing 
an integrated approach, we uncovered distinct mutation, gene expression, and drug response 
profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. Recurrent 
intragenic deletions of PAX5 or VPREB1 were identified in constellation with TCF3-HLF. 
Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene 
dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The 
enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect 
reprogramming by TCF3-HLF of a lymphoid-committed cell of origin towards a hybrid, drug-
resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts 
revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics, 
but sensitivity towards glucocorticoids, anthracyclines and agents in clinical development. 
Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax 
(ABT-199). This integrated approach thus provides alternative treatment options for this deadly 
disease.
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One of the hallmarks of pediatric ALL is the presence of subtype-defining chromosomal 
translocations that cause gene fusions involving master regulators of hematopoietic 
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development. These initiating lesions often cooperate with specific somatic aberrations 
including monoallelic deletions of B-cell developmental genes, such as PAX5, IKZF1 and 
EBF11. Other cooperative liaisons are represented by trisomy 21q22 with CRLF2 
activation2-4 or near-haploid ALL with activation of receptor tyrosine kinase or RAS 
signaling5. RAS pathway mutations appear in high-risk ALL, but are often lost with disease 
progression, suggesting the involvement of additional tumorigenic factors6,7. The patterns of 
recurrent genomic alterations need to be better understood, because apart from tyrosine 
kinase inhibitor-supplemented treatment of BCR-ABL1-positive ALL, the only proven 
successful first-line treatment strategies for high-risk ALL are chemotherapy intensification 
and early allogeneic hematopoietic stem cell transplantation8.
The translocation t(1;19)9 that fuses the transcriptional activation domain of the B cell 
developmental transcription factor TCF3 to the DNA-binding domain of PBX1 occurs in 
about 5-10% of precursor B cell (pre-B) ALL patients and is associated with a median five-
year event-free survival probability of 78-85%10. In contrast, the translocation t(17;19)
(q22;p13), resulting in the fusion gene TCF3-HLF, defines a rare subtype of ALL (<1% of 
pediatric ALL) that is typically associated with relapse and death within two years from 
diagnosis11,12. Both translocations disrupt one allele of TCF3, which drives the B-cell 
differentiation program upstream of the transcription factor PAX513. As an initiating event, 
expression of TCF3-HLF leads to transcriptional reprogramming in pre-leukemic cells. 
Possible direct targets of TCF3-HLF include the transcription factor gene LMO2, which is 
implicated in initiation of T ALL14,15, and the transcriptional repressor SNAI1 (SLUG), 
which regulates embryonic development and apoptosis16,17. Further targets were proposed, 
including BCL214. The TCF3-HLF fusion likely requires additional events to cause 
leukemia, because TCF3-HLF transgenic and knock-in mice did not recapitulate the human 
phenotype18,19.
Here, we report that the genomic and transcriptomic landscape of TCF3-HLF-positive ALL 
differs markedly from TCF3-PBX1-positive ALL. The TCF3-HLF fusion likely occurs in B 
lymphoid progenitors in the context of PAX5 haploinsufficiency and is associated with 
transcriptional reprogramming towards an immature, hybrid hematopoietic state. Drug 
response profiling in patient-derived xenografts, which maintained the genomic and global 
transcriptome landscapes of the corresponding primary leukemic samples, identified 
resistance patterns to drugs commonly used for the treatment of TCF3-HLF-positive 
patients. A general trait of TCF3-HLF-positive ALL in our study is extreme sensitivity 
towards the BCL2-specific inhibitor ABT-199 (venetoclax), indicating new therapeutic 
options for this fatal ALL subtype.
RESULTS
Next generation sequencing (NGS) analysis integrating short and large insert size paired-end 
whole genome (WGS), whole exome (WES) and transcriptome (RNAseq) sequencing was 
applied to a discovery cohort consisting of five diagnostic pre-treatment samples of TCF3-
PBX1-positive (samples 1a-5a) and TCF3-HLF-positive (samples 6a-9a and 11a) ALL, 
respectively. Matched bone marrow samples collected after induction treatment for minimal 
residual disease evaluation (MRD, maximum leukemic cell load ≤10−3; samples 1b-9b and 
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11b) were used as non-tumor controls (Supplementary Table 1). Additional DNA samples 
from seven TCF3-HLF-positive (diagnostic samples 10a, 12a, 13a, 14a, 15a, 16a, 17a, 
remission samples 10b, 12b, 13b) and 24 TCF3-PBX1-positive cases were used for 
validation (Supplementary Tables 2 and 3). In most cases TCF3-HLF-positive ALL 
responded to induction chemotherapy, but remained MRD positive. Nine children included 
in this study died due to disease progression and treatment-related toxicities within 2 years 
on average and only one patient is in remission after a short follow-up time, reflecting the 
dismal prognosis of TCF3-HLF-positive ALL.
TCF3 breakpoints suggest a committed lymphoid cell of origin
Consistent with previous reports20,21, all TCF3 translocation breakpoints were restricted to 
three hotspot regions (Fig. 1a and 1b and Supplementary Fig. 1). Those were associated with 
small non-template nucleotide insertions indicative of terminal deoxynucleotide transferase 
(TdT) activity characteristic of an early B cell stage (Supplementary Table 4). In TCF3, the 
breakpoints clustered in close proximity to CpG elements in the absence of classical RAG 
consensus sequence sites (Supplementary Fig. 1), which is a characteristic feature of 
translocations that occur in lymphoid progenitors at the pro-/pre-B stage. This may represent 
illegitimate RAG-mediated recombination at cryptic sites, possibly in the context of 
deaminated CpG nucleotides as proposed for TCF3-PBX1 translocations22. Consistent with 
the idea that TCF3-HLF may occur at a lymphoid-committed rather than a pluripotent 
progenitor stage, we detected this translocation only in sorted pre-B cell populations 
containing leukemic cells but neither in stem cells nor in myeloid progenitor cells 
(Supplementary Fig. 2).
TCF3-HLF ALL and impaired pro- to pre-B cell transition
Pre-B cell ALL is frequently associated with somatic copy number alterations affecting B 
cell developmental genes. PAX5 deletions are generally observed in 13% of ALL cases and 
in up to 28% of high-risk ALL23. We observed enrichment for monoallelic PAX5 deletions 
in TCF3-HLF-positive ALL reaching 67% of the cases (Fig. 1c, Supplementary Table 2). 
Illegitimate RAG-mediated recombination appears to be implicated in the generation of such 
events in TCF3-HLF-positive ALL given the close proximity to RSS motifs (Supplementary 
Table 5). In most samples without PAX5 deletion, we identified hemi- and homozygous 
deletions of VPREB1, a component of the surrogate light chain of the pre-B cell receptor 
(Fig. 1c, Supplementary Table 6) independent of the lambda light chain locus. VPREB1 
deletions in pediatric ALL result in failure to form a viable surrogate light chain in the pre-B 
cell receptor, an event associated with lower overall survival24. In addition, we detected 
BTG1 gene deletions in three out of eight TCF3-HLF-positive cases without PAX5 deletions 
(Supplementary Fig. 3a and 3b). BTG1 deletions occur frequently in ALL positive for ETV6-
RUNX1 (19%) or BCR-ABL1 (26%) and may confer a proliferative advantage25. In contrast, 
no deletion, but only a single PAX5 nonsense mutation could be detected in 29 TCF3-PBX1-
positive cases (Fig. 1 and Supplementary Table 3). Our results indicate that cooperative 
genetic events affecting genes regulating the pro- to pre-B cell transition, in particular PAX5, 
BTG1 and VPREB1, but not IKZF1, are selected in TCF3-HLF-translocated cells. Other 
deleted genes associated with pre-B cell ALL26 were JAK2 and CDKN2A/B (patient 7a and 
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11a) and transcriptional regulators such as ERG, NCOR1, TOX, BACH2, BCL7C, MLLT3, 
SMARCA2, and MAFK (Fig. 1c).
Recurrent RAS pathway mutations in TCF3-HLF ALL
We identified only a few additional somatic alterations affecting protein-coding sequences 
in both TCF3-PBX1- and TCF3-HLF-positive ALL (Fig. 1c, Supplementary Tables 6 and 7), 
involving among others, genes associated with pre-B cell ALL26 (TCF3, PAX5, LEF1) and 
transcriptional and chromatin regulation (ZNF263, MLL2, HIST1H3A, C6orf89). We 
observed a prominent association of TCF3-HLF-positive ALL with activating mutations in 
RAS signaling pathway genes (NRAS, KRAS, and PTPN11), detectable in four out of five 
discovery cases (Fig. 1c) and in three out of five additional TCF3-HLF-positive validation 
samples (PTPN11 and SPHK1) (Supplementary Table 2). No RAS pathway mutations were 
identified in the TCF3-PBX1-positive discovery cohort and only one oncogenic NRAS 
mutation was detected in the 24 TCF3-PBX1-positive validation cases (Supplementary 
Table 3). NRAS and KRAS mutations were generally detected in subclones (Supplementary 
Table 7). Interestingly, we discovered a novel fusion gene, KHDRBS1-LCK, due to an 
interstitial chromosomal deletion in one TCF3-HLF-positive sample (6a), triggering the 
overexpression of the LCK tyrosine kinase (Supplementary Fig. 4). This was also present in 
three out of 74 randomly selected ALL samples, demonstrating that KHDRBS1-LCK fusion 
is recurrent in ALL (Supplementary Fig. 5). LCK is a drug target in RAS-dependent cancer 
cells which have higher LCK expression27, suggesting a possible interplay with RAS-related 
signaling networks in TCF3-HLF-positive ALL. Oncogenic activation of LCK associated 
with t(1;7)(p34;q34) translocation was reported in the T cell leukemia cell line HSB228. Our 
data indicate a frequent association of proliferation-driving mutations in TCF3-HLF-positive 
ALL in the context of stalled B cell differentiation.
Mutations affecting the second TCF3 allele in TCF3-HLF ALL
We identified a mutation in the basic helix-loop-helix region of TCF3 (p.Asp561Val, 
D561V, Fig. 1c and 1d) affecting the non-translocated chromosome in one TCF3-HLF-
positive case (8a). Mutations at this position were reported in sporadic Burkitt lymphoma29 
and may reduce binding to its negative regulator ID329. Based on available crystal structure 
data, p.Asp561Glu may affect the interaction of TCF3 with the transcription factor SCL 
(also known as TAL1; Fig. 1d), possibly altering TCF3 protein complexes. A second TCF3 
mutation (p.Ser467Gly) was detected in another TCF3-HLF-positive case (13a, 
Supplementary Table 2). The functional consequences of this mutation are currently unclear. 
Interestingly, we could not detected any somatic mutations in TCF3 by targeted sequencing 
of 1,033 unselected ALL patients from the European multicenter trial AIEOP-BFM ALL 
2000, suggesting a specific association with TCF3-HLF-positive ALL (Supplementary 
Table 8). Thus, deregulation of normal TCF3 function may also contribute to TCF3-HLF-
positive ALL. Corroborating our findings, a recent study included a single TCF3-HLF case, 
as part of a cohort comparing diagnostic and relapse ALL samples, which showed a PAX5 
deletion and two mutations in TCF3 (p.His460Tyr, p.Gly470fs), all of which were 
conserved at relapse30. Besides, the relapse sample featured a VPREB1 deletion as well as a 
shift in subclonal mutations in NRAS (p.Gly12Asp and p.Gly12Val), reinforcing the idea of 
Fischer et al. Page 4
Nat Genet. Author manuscript; available in PMC 2016 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
cooperative effects between TCF3-HLF and alteration of PAX5 and VPREB1 gene dosage. 
Taken together, seven out of eleven TCF3-HLF cases were hemizygous for PAX5, whereas 
five samples featured VPREB1 deletions (summarized in Supplementary Fig. 6).
Reprogramming towards a more immature state in TCF3-HLF ALL
Consistent with the occurrence of TCF3-HLF and TCF3-PBX1 translocations in lymphoid 
precursors, both leukemia subtypes shared a gene expression signature of B-lymphoid cells 
(including PAX5, BLK, CD19, CD22, CD79B, TCF3, EBF1, VPREB1, RAG1, ROR1, BLNK, 
and DNTT) (Supplementary Tables 9 and 10), but differential expression of 401 genes (false 
discovery rate ≤ 0.001) strongly distinguished the two TCF3-translocated subtypes (Fig. 2a, 
Supplementary Tables 11 and 12). In silico prediction of transcription factor binding sites 
(TFBS) in the corresponding promoter regions revealed significant enrichment for PBX and 
HLF binding motifs associated with TCF3-PBX1- and TCF3-HLF gene signatures, 
respectively (Supplementary Tables 13 and 14). Further, PBX1 and HLF were the only 
transcription factors among those with enriched binding motifs which were significantly 
differentially expressed between the two ALL subtypes and between leukemia and 
remissions. The chimeric HLF transcript was strongly induced in TCF3-HLF, but no wild-
type HLF expression could be detected. We predicted 39 potential HLF targets, including 
the known target SNAI2 (SLUG)16, GPC4 and BMP3 involved in stem cell proliferation, 
which showed induced expression in TCF3-HLF samples (Supplementary Table 15). Other 
potential TCF3-HLF targets that regulate developmental programs and cell survival, such as 
LMO214 and BCL214, were not predicted. However, their expression was increased in 
TCF3-HLF-positive ALL.
Gene set enrichment analysis (GSEA) using gene sets from sorted human hematopoietic 
stem cells (HSC) and early progenitor populations31 as well as curated oncogenic (C6) and 
human immunologic (C7) signatures from MsigDB32 revealed an enrichment for stem cell 
and myeloid signatures in TCF3-HLF-positive ALL. In contrast, lymphoid features were 
more prominent in TCF3-PBX1-positive ALL (Fig. 2b, Supplementary Table 16). The HSC 
signature l31 ranked among the top gene sets enriched in TCF3-HLF-positive ALL (Fig. 2c, 
Supplementary Table 17). We obtained similar results using an independent method based 
on text mining annotations (Fig. 2d, Supplementary Tables 18 and 19). High expression of 
the stem cell marker LGR533 was consistently detected in TCF3-HLF-positive ALL 
suggesting a reactivation of immature features shared with other stem cell populations. 
Consistent with previous reports, the myeloid marker CD33 was expressed in TCF3-HLF-
positive blasts, which provides a target for antibody-directed therapy12,34. Other 
differentially expressed genes, such as BMP235, could present additional therapeutic targets.
Our results are consistent with a model in which TCF3-HLF arises in lymphoid cells and 
promotes transcriptional reprogramming towards a hybrid hematopoietic state. Features of 
mesenchyme-derived tissues were also detected in TCF3-HLF-positive ALL, which may 
indicate a profound cellular reprogramming towards a drug-resistant state.
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Mutation profiles of TCF3-HLF ALL are conserved in xenografts
We generated leukemia xenografts in immunodeficient NOD/SCID/IL2rγnull (NSG) mice 
for all cases included in this study (Supplementary Table 20)36,37. We also established for 
the first time to our knowledge leukemia xenografts from follow-up samples with MRD, 
some with less than 0.1% ALL cells after induction chemotherapy (Fig. 3a and 
Supplementary Tables 1 and 20). Leukemia and MRD engraftment was rapid with 
conserved and predictable kinetics for xenografts derived from the same patient 
(Supplementary Fig. 7), suggesting that no major adaptation to the mouse microenvironment 
was needed for proliferation. Most SNVs and intrachromosomal deletions that were present 
at diagnosis were conserved in the corresponding xenografts (Fig. 3b, Supplementary Table 
7). Only deletions detected in the relapse sample 11c were not conserved in the 
corresponding xenografts and a deletion in BTG1 emerged in one MRD-derived sample 
(patient 7b, Supplementary Fig. 3c and 3d). A few mutations were lost in MRD or relapse 
xenograft samples, including GNB1 and DDX3X indicating that these are probably 
dispensable or may cause drug sensitivity. Mutations in the RAS pathway were largely 
maintained in xenografts. However, the NRAS mutation p.Gln61His identified in the primary 
MRD sample 7b was not detected in the corresponding xenograft. Interestingly, a 
heterozygous damaging mutation in KRAS (p.Lys147Glu) associated with Noonan 
syndrome38 emerged instead. In patient 9a we identified two subclones displaying either a 
KRAS (p.Gly13Asp) or an NRAS (p.Gly12Ser) mutation. The corresponding xenograft 
retained only the KRAS mutated sub-clone. Thus, maintenance and acquisition of RAS 
pathway mutations in xenografts support the notion that they occur later during selection at a 
multiclonal level and confer a selective advantage in TCF3-HLF-positive ALL. No other 
SNVs emerged de novo in the xenografts. In summary, the molecular characteristics of both 
leukemia subtypes were largely conserved in the xenografts, confirming the validity of this 
model.
TCF3-HLF-associated gene expression is maintained in xenografts
Hierarchical clustering based on the gene signature specifying the two leukemia subtypes 
showed that the expression profile and the subtype-specificity of the primary leukemia were 
maintained in the xenografts (Fig. 4). The genes most significantly upregulated in matched 
patient and xenograft samples from TCF3-HLF-positive leukemia specified stem cell 
features (Supplementary Table 21 and 22). Similar to patient samples, features of 
mesenchyme-derived tissues were also detected in xenografts derived from TCF3-HLF-
positive ALL. Strikingly, TCF3-HLF-positive leukemias and xenografts displayed 
systematic down-regulation of PAX5 expression to halved levels. Though mono-allelic 
deletions of PAX5 were a prominent feature of TCF3-HLF-positive ALL, reduced 
expression was also seen in diploid cases, hinting at alternative molecular mechanisms. The 
recapitulation of this pattern in the xenograft samples enforces the notion that TCF3-HLF-
positive leukemia emerges in a specific cellular context with reduced PAX5 expression 
(Supplementary Fig. 8). The essential molecular features of TCF3-HLF-positive samples 
were maintained in xenografts, providing a useful model of this disease.
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Drug activity profiling of TCF3-HLF and TCF3-PBX1 ALL
To determine drug sensitivity and resistance profiles, we established ALL co-cultures on 
human mesenchymal stromal cells (MSC) under serum-free conditions.39 Both subtypes 
depend on stroma for survival (Supplementary Fig. 9). TCF3-PBX1-positive ALL had a 
higher proportion of cells in S-phase than TCF3-HLF-positive ALL on such cultures, 
reflecting consistent biological differences. By screening 98 bioactive agents, including 
many agents in clinical development (Supplementary Table 23), on an automated-
microscopy-based platform, we unambiguously discriminated the two translocations based 
on their drug sensitivity profiles, using either single (logIC50, Fig. 5a, Supplementary Fig. 
10) or multiple response parameters (logIC50, logEC90, logEC50 and AUC, Fig. 5b and 
Supplementary Table 24). To capture informative differences, we compared the responses of 
xenografts derived from TCF3-HLF-positive ALL to xenografts derived from other high-
risk pre-B and T ALL patients on the same platform (Fig. 5c and Supplementary Table 25). 
This provided information about the activity range of each drug on the respective ALL 
subtype. TCF3-HLF-positive cases were consistently more resistant to various drugs from 
the same class, including nucleotide analogs (e.g. cytarabine), mitotic spindle inhibitors (e.g. 
vincristine), polo-like and aurora kinase inhibitors. Given the importance of cytarabine and 
vincristine in standard ALL therapy, the implications of these observations need to be 
further explored. TCF3-HLF-positive ALL was very resistant to dasatinib in this assay, 
while TCF3-PBX1-positive ALL responded well. This partly challenges a recent report,40 
which proposed dasatinib as an alternative for the treatment of these leukemias based on 
strong in vitro activity in one TCF3-HLF- and ten TCF3-PBX1-positive primary ALL 
samples. However, in vivo studies will be required to verify these differences in drug 
response, as differences in cell cycle activity may influence the pattern of response in vitro.
TCF3-HLF-positive ALL were sensitive to glucocorticoids (prednisone, dexamethasone) 
and to other drugs that could be relevant for the treatment of resistant ALL, including 
mTOR inhibitors, anthracyclines, bortezomib, the HSP90 inhibitor AUY922, and 
panobinostat. However, in spite of the good response of patients with TCF3-HLF-positive 
leukemia to prednisone therapy and the observed responsiveness of TCF3-HLF-positive 
ALL cells to glucocorticoids and anthracyclines that are commonly used in ALL treatment, 
patients eventually will relapse. Our transcriptome data suggested that resistance to 
apoptosis due to high expression of the anti-apoptotic oncoprotein BCL2 might promote 
cancer cell survival and constitute a druggable target (Supplementary Fig. 11). BCL2 is a 
putative transcriptional target of TCF3-HLF14. Of note, PAX5, commonly deleted in our 
cohort, normally represses BCL2 transcription41.
TCF3-HLF ALL is extremely sensitive to the BCL2 antagonist venetoclax
To assess the role of BCL2 overexpression in TCF3-HLF-positive ALL and to provide 
preclinical evidence for therapeutic activity, we tested the BCL2-targeting drug venetoclax 
(ABT-199) in our xenograft model (Fig. 5c). This BH3-mimetic compound is a highly 
specific small molecule inhibitor that competes with pro-apoptotic BCL2 family proteins for 
binding to BCL2 and shifts the balance of pro-death and pro-survival signals inside the cell 
in favor of cell death42. Venetoclax is in clinical development (phase II and III trials) for 
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chronic lymphocytic leukemia and lymphoma, and holds promises for ALL and acute 
myeloid leukemia (AML).
TCF3-HLF-positive ALL samples were more sensitive to venetoclax than TCF3-PBX1-
positives (Fig. 6a), which correlated with higher BCL2 transcript and protein expression 
levels (Fig. 6b). A two-week treatment course of daily venetoclax administration delayed 
leukemia progression significantly in ALL xenografts from three different TCF3-HLF-
positive cases (Fig. 6c and 6d). Treatment of mice in the control arm that reached maximal 
leukemia burden resulted in very rapid reduction of the leukemic load (Fig. 6e). Xenografts 
from MRD or relapse remained sensitive to venetoclax (Supplementary Fig. 11). Profiling of 
primary cells from two additional cases with refractory ALL confirmed exquisite sensitivity 
to venetoclax (Supplementary Fig. 12). Combined treatment of patient-derived xenografts 
from patients 6 to 11 with venetoclax and either vincristine or dexamethasone indicated a 
potentially synergistic effect in some of those patients (Supplementary Fig. 13, 
Supplementary Table 26). Our data identify BCL2-dependency in TCF3-HLF ALL as a 
druggable target and illustrate how integration of drug response profiling and molecular 
genetic analyses can inform the development of innovative treatment strategies in patients 
with unmet therapeutic needs.
DISCUSSION
To our knowledge, long-term cure has never been achieved for patients with TCF3-HLF-
positive ALL. Our study revealed a recurrent pattern of TCF3-HLF accompanied by 
abnormalities that affect transcriptional regulation of lymphoid development. We found 
frequent deletions of PAX5 and VPREB1 in association with TCF3-HLF, but deletions of 
Ikaros family members, which are commonly affected in ALL1,23, were not detected. We 
also uncovered recurrent mutations of the transcription factor TCF3, which acts upstream of 
PAX5 in lymphoid development, potentially impairing structural interactions with other 
transcription cofactors29. PAX5 expression was reduced by two-fold in all TCF3-HLF-
positive cases, underscoring the possibility of an interaction between TCF3-HLF, TCF3 and 
PAX5. PAX5 is required for B-lymphoid lineage commitment and maturation43 and 
frequently deleted in high-risk ALL with complex patterns of copy number abnormalities23. 
Similarly, deletions in IKFZ1, which is required for the development of B- and T-lymphoid 
lineages and has additional stem cell-like functions44, are detected both in high-risk BCR-
ABL1-positive and -negative ALL and in the more favorable ERG-altered ALL subtype45, 
but never in TCF3-HLF-positive ALL. Focal deletions of VPREB1 were also detected in 
TCF3-HLF ALL which may lead to a developmental arrest associated with lack of pre-B 
cell receptor formation and the resulting loss of negative feedback on RAG-mediated 
recombination46. VPREB1 deletions were present at a similar frequency compared to other 
high-risk ALLs, such as BCR-ABL1-like and BCR-ABL1-positive ALL (approximately 
30-40% of cases)47 or hypodiploid ALL (≈30%)24, associated with poorer overall survival 
in high-risk pre-B cell ALL patients24. However, specific ALL subtypes associated with 
good prognosis (e.g. ETV6-RUNX1-positive ALL) also present high frequencies of VPREB1 
deletions24, suggesting an important impact of the genomic context24. Thus, distinct patterns 
of association emerge that are likely to reflect important underlying biological mechanisms. 
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Based on our results, we propose that a reduction of PAX5 gene dosage constitutes a 
favorable context for the oncogenic activity of TCF3-HLF.
As observed for hypodiploid ALL5 and in subsets of MLL-rearranged ALL48, we identified 
mutations in NRAS, KRAS and PTPN11 in TCF3-HLF-positive ALL. In our xenograft 
models we detected variable persistence of NRAS and a switch to KRAS mutations, 
indicating that RAS mutations are multiclonal and might not be strictly required for disease 
progression in TCF3-HLF-positive ALL. Indeed, mutations in the RAS pathway are 
enriched at relapse in ALL7,30,48, but mostly in a subclonal pattern with losses or switches in 
NRAS and KRAS from diagnosis to relapse. These represent secondary events, possibly 
compensating functional effects of the initiating events. Mutations in the RAS pathway 
might not represent optimal therapeutic targets, given their volatility and the potential to 
select for slower proliferating, more resistant subclones. The TCF3-HLF gene expression 
signature, enriched for components of stem cell and myelomonocytic stages, was very 
similar among leukemias and maintained in xenografts, specifying additional, novel markers 
associated with stem cell function, such as LGR5, which marks epithelial stem cells49 and 
embryonic and fetal hematopoietic progenitor cells in mice50. Thus, in analogy to 
experimental induction of pluripotent stem cells51,52, TCF3-HLF likely induces a whole set 
of factors that carry out reprogramming and leukemic transformation in the context of low 
PAX5 expression. Deletion of PAX5 in early B cell progenitors induced dedifferentiation to 
a state with myeloid and T cell potential43,53. Moreover, rescue with low expression levels 
of PAX5 in knock-out mice generates a stalled biphenotypic B-lymphoid/myeloid state54. 
Together with an activating mutation in STAT5, PAX5 haploinsufficiency initiates ALL in 
mice41. Based on these data, we propose that the initiating TCF3-HLF fusion results in 
severe transcriptional reprogramming with dedifferentiation. The favorable context for 
transformation is secured in second line through additional lesions in early B cell 
differentiation genes including TCF3 and PAX5.
A central question remains pertaining to the cell of origin in different ALL subtypes. Our 
study provides significant clues that should be further addressed using disease models. The 
molecular analysis of the TCF3-HLF and TCF3-PBX1 fusion gene breakpoints indicated 
that the TCF3-HLF, like the TCF-PBX1 translocation, originates in cells already committed 
to lymphoid differentiation. Furthermore, the associated somatic structural variants were 
found to be RAG-mediated, which is comparable to patterns identified recently in ETV6-
RUNX1-positive ALL, the most frequent pre-B cell ALL subtype, which is consistent with 
expression of RAG in TCF3-HLF-positive ALL55. We favor the hypothesis that the TCF3-
HLF translocation occurs in a B cell progenitor and that the specific lineage context is 
constrained further in a restricted developmental stage by additional mutations. The 
detection of TCF3-HLF being restricted to leukemic cells supports this idea, although 
initiation in a more immature compartment cannot be formally excluded.
The molecular landscapes of TCF3-HLF-positive ALL were largely conserved in 
xenografts, providing a valuable, well characterized, model for preclinical testing. Drug 
activity profiling revealed that TCF3-HLF-positive cases were more resistant to several 
standard ALL drugs, such as nucleotide analogues (e.g. cytarabin) and mitotic spindle 
inhibitors (e.g. vincristine). Activity was detected for other relevant drug classes, such as 
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mTOR inhibitors, the proteasome inhibitor bortezomib, the HSP90 inhibitor AUY922, and 
the HDAC inhibitor panobinostat. The BCL2 inhibitor venetoclax (ABT-199)42 was highly 
active in all TCF3-HLF-positive cases analyzed, which we confirmed using primary ALL 
cells from two additional cases with refractory disease. These results refine data obtained 
using the broader spectrum BH3-mimetic ABT-737 in TCF3-HLF-positive cell lines14. 
Given the activity of venetoclax also in other ALL subsets including immature T ALL (56,57 
and own unpublished data) and the lack of on-target thrombocytopenia caused by ABT-737, 
venetoclax should be explored for experimental therapy in refractory ALL in selected cases 
based on such functional data. Thus integrated genomic and functional analyses of TCF3-
HLF-positive ALL provide novel insight into the molecular context and associated 
components and offer unprecedented possibilities to investigate new agents for the treatment 
of these children who currently lack effective therapeutic options.
ONLINE METHODS
Study individuals and sample selection
Samples and associated clinical information from patients included in sequencing and 
validation analyses were collected from different countries within the International BFM-
Study Group (IBFM-SG). All patients were enrolled in multicenter trials on treatment of 
pediatric ALL conducted by individual member groups of the I-BFM-SG: the AIEOP-BFM 
study group (Austria, Germany, Italy, Switzerland), the FRALLE study group (France), and 
the United Kingdom (UK) National Cancer Research Institute (NCRI) Childhood Cancer 
and Leukaemia Group61,62. All treatment trials were approved by the respective national 
institutional review boards and informed consent for the use of spare specimens for research 
was obtained from study individuals, parents or legal guardians. The specific research 
project reported here was approved by the Ethics Committee of the Medical Faculty of the 
Christian-Albrechts-University, Kiel, Germany (vote D508/13). Depending on consent and 
availability of samples, all enrolled patients positive for the rare TCF3-HLF gene fusion 
were included. These patients were matched with TCF3-PBX1-positive patients. Download 
of sequencing data is available from the public POPGEN repository (Christian-Albrechts-
University, Kiel) upon written request accompanied by a positive internal review board vote 
for research addressing leukemia-related questions. Data transfer can proceed upon positive 
review and signing of a material transfer agreement.
Cell isolation and nucleic acid purification
Mononuclear cells (MNCs) were isolated by Ficoll-Paque gradient centrifugation 
(Pharmacia) from bone marrow or peripheral blood samples followed by extraction of 
nucleic acids according to standardized protocols using Qiagen DNA Blood Kits (Qiagen) 
for DNA and Qiagen RNeasy columns (Qiagen) for RNA. The quantity of nucleic acids was 
determined by spectrophotometry. DNA quality was assessed visually by inspection of 
agarose gel electrophoresis while RNA integrity was evaluated by using the Bioanalyzer 
2100 (Agilent). Nucleic acids isolated from bone marrow aspirates collected in 
morphological remission served as individual germline surrogates/references.
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Sequencing
Whole genome sequencing—For structural variants (SVs), Illumina v2 mate-pair 
libraries with 5 kbp insert size and 2 × 101 bp reads were prepared from 10 μg of DNA and 
sequenced on the Illumina HiSeq 2000 platform (Illumina) to obtain a physical coverage of 
30x. For copy number alterations, breakpoints and short variants (SNVs, short indels), 
Illumina TruSeq paired-end libraries with 2 × 101 bp reads were prepared from 1 μg of 
DNA and sequenced on HiSeq 2000/2500 instruments to a coverage of 40x for reference 
samples and 80x for tumor samples.
Whole exome sequencing—For increasing the sensitivity of detecting short variants in 
coding regions, 1 μg of DNA each from the diagnostic leukemic and a corresponding 
remission sample of patients was used for whole exome sequencing. Whole exome capture 
employed a TruSeq enrichment kit (Illumina) and paired-end libraries with 2 × 101 bp reads 
on a HiSeq 2500 according to the manufacturer’s protocol.
Whole transcriptome sequencing—Illumina TruSeq custom stranded paired-end 
libraries with 2 × 51 bp reads were prepared from 1 μg RNA using the Ribo-Zero Gold Kit 
(Epicentre) and sequenced on a HiSeq 2000 with a loading of one library per lane.
Sanger sequencing validation—Structural variant breakpoints from mate-pair genome 
sequencing and SNVs from exome sequencing were validated by Sanger sequencing.
Targeted sequencing of TCF3 and RAS pathway candidate genes—TCF3 
binding domain (E47 isoform, exon 18) mutations were screened for in 1033 ALL patients 
using Sanger sequencing. Primer sequences are listed in Supplementary Table 27. Sanger 
sequencing was also applied for validation of relative absence of RAS pathway mutations in 
24 TCF3-PBX1-positive ALL samples. The latter analysis included KRAS exon 1, NRAS 
exons 1 and 2, FLT3 exons 14 and 20, PTPN11 exons 3 and 13 and was conducted as 
previously described63.
Multiplex Ligation-dependent Probe Amplification
Detection of genomic aberrations in B cell differentiation-associated and other genes 
frequently deleted in ALL (PAX5, IKZF1, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, 
and P2RY8-CRLF2) were investigated by the Multiplex Ligation-dependent Probe 
Amplification (MLPA) assay SALSA p335 kit (MRC-Holland) using 125 ng of genomic 
DNA. The assays were performed according to the manufacturer’s protocol as previously 
described64. An intensity ratio between 0.75 and 1.3 was considered to represent a normal 
copy number, a ratio between 0.25 and 0.75 a monoallelic deletion, and a ratio <0.25 a 
biallelic deletion.
Bioinformatic analysis
DNA data processing—DNA reads were aligned to the human reference genome hg19 
(downloaded from the UCSC Genome browser) using Elandv265 (mate-pairs) and BWA66 
(paired-ends). For xenograft samples, the human DNA reads were deconvoluted after 
mapping to a combined reference consisting of human hg19 and mouse mm9.
Fischer et al. Page 11
Nat Genet. Author manuscript; available in PMC 2016 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Structural variant detection—Structural variants (SVs) were detected using DELLY67 
and BIC-seq68 (DNA data) and TopHat269/deFuse70 (RNA data).
SNV detection—Somatic protein-changing SNVs were detected using established 
pipelines incorporating GATK71, MuTect72, pibase73, Picard, SAMtools74 and VarScan275.
Indel detection—Somatic indels in coding regions were detected using SAMtools 
followed by Dindel76.
Transcriptome data analysis—RNA reads were aligned to hg19 using BWA and 
SAMtools and used for integrated data analysis. For xenograft samples, the human RNA 
reads were deconvoluted after mapping to a combined reference consisting of human hg19 
and mouse mm9. Mapped reads were annotated using Ensembl v.70. Gene expression levels 
were quantified in reads per kilobase of exon model per million mapped reads (RPKM)77. 
RPKM calculation and differential gene expression (DGE) analysis was performed using the 
R package edgeR78. To identify DGE between ALL subtypes, and between leukemia and 
remission the following set-up was performed: TCF3-PBX1 vs. TCF3-HLF (comparison 1), 
TCF3-PBX1 vs. remission (comparison 2), TCF3-HLF vs. remission (comparison 3). The 
results were filtered by fold change (FC, |log2(FC)| >= 1) and false discovery rate (FDR, 
FDR <= 0.001). The final list of 401 genes was created by combining the intersection 
between comparison 1 and comparison 2 as well as between comparison 1 and comparison 
3. The functional analyses of gene lists were done using Gene Set Enrichment Analysis 
(GSEA)59 and the Genomatix genome analyzer (v. 3.00801; Genomatix Software GmbH). 
The GeneRanker tool in Genomatix was used to test for enriched gene sets, which were 
based on gene-tissue annotations obtained by text mining60. For GSEA, protein-coding 
genes were filtered by a minimum expression of 1 RPKM in at least four samples among the 
primary pre-B cell ALLs. The remaining 11315 genes were tested for DGE between the 
ALL subtypes using edgeR. The provided FDR and fold-change values were used to obtain 
a ranking score to measure the degree of differential expression between the ALL subtype. 
A pre-ranked classic GSEA was performed using the ranking score, a gene set permutation 
and a FDR ≤ 0.02. The analysis included gene sets for hematopoietic stages31 and signatures 
from MsigDB59 pathways (C2): KEGG, BIOCARTA, REACTOME; curated oncogenic 
signatures (C6); human immunologic signatures (C7).
In silico transcription factor binding site (TFBS) analysis—TFBS in promoter 
regions of genes (2 kbp upstream region) corresponding to the specific transcriptome 
signatures of TCF3-PBX1- and TCF3-HLF-positive ALL, respectively, were analyzed using 
the Genomatix Genome Analyzer (v3.10124). Based on a matrix of known TFBS motifs, the 
software tool predicted TFBSs in the investigated promoters and compared their frequency 
against 1) the background of TFBSs in the promoter regions of all known protein-coding 
genes in the Ensembl database (v.70, 22864 genes) and 2) the background of TFBSs in the 
whole genome. A Z-score was calculated based on the TFBS frequency in the investigated 
promoters and the expected frequency and standard deviation were estimated from the 
background79. The resulting lists were filtered by the Z-scores based on the two 
backgrounds ( |genomic Z-score| ≥ 2 , promoter Z-score ≥ 2 ). TFBSs overrepresented in 
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genes up-regulated in both TCF3-PBX1- and TCF3-HLF-positive ALL were filered out, to 
retain only TFBS specifically enriched in the respective subtypes.
Integrated data analysis—SNVs and indels were orthogonally validated by integrating 
genome, exome, and transcriptome data of patients and xenografts and further confirmed by 
Sanger sequencing. SVs were validated by integrating whole genome paired-end and mate-
pair data and whole transcriptome data and finally by Sanger sequencing. Ensembl v.70 and 
ANNOVAR80 were used to annotate the variants. Silent variants and known germline 
variants in the 1000 Genomes Project81 population data, in 136 North German healthy 
controls (publicly available through GrabBlur82), or in the International Cancer Genome 
Consortium’s internal healthy controls were eliminated. All final somatic non synonymous 
variants were inspected using IGV83.
Preclinical characterization
Xenograft model—Animal experiments were approved by the veterinary office of the 
Canton of Zurich, Switzerland. Approval for experiments with human samples in the mouse 
xenograft model was obtained from the ethics commission of the Canton Zurich (approval 
number 2014-0383). In brief, primary ALL cells were recovered from cryopreserved 
samples and transplanted intrafemorally to NSG mice as previously described36. Mice were 
between 5 to 10 weeks old, both males and females were randomly used. Leukemia 
progression was monitored by flow cytometry with rat anti-mouse CD45 (eFluor®450, 
Clone 30-F11, REF 48-451-82, eBioscience), mouse anti-human CD45 (AlexaFlour647, 
Clone HI30, REF 304018, BioLegend), and mouse anti-human CD19 (PE, Clone HIB19, 
REF 302208, BioLegend). ALL cells recovered from spleens of NSG mice were used for 
molecular characterization in in vitro and in vivo experiments.
Immunophenotyping—Immunophenotyping of patient and xenograft-amplified human 
ALL cells after recovery from the spleen was performed as described before84. All included 
xenograft samples consisted of at least 95% human leukemic cells.
Cell culture—Human hTERT immortalized primary bone marrow mesenchymal stromal 
cells (MSC; provided by D. Campana, St. Jude Children’s Research Hospital, Memphis, 
TN) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum (FBS h.i.); L-glutamine (2 mM), penicilline/streptomycin (P/S; 100 IU/ml) 
and hydrocortisone (1 μM). Xenograft-amplified human ALL cells were co-cultured on 
MSC in AIM V medium (Gibco by Life Technologies) at a ratio of 10:1. All cultured cells 
were kept in the incubator at 37°C, 5% CO2. For cryopreservation, cells were frozen in FBS 
h.i. with 10% dimethylsulfoxide and subsequently stored in liquid nitrogen.
Cell viability assay—MSCs were seeded in 24-well plates at a number of 50,000 cells per 
well in RPMI 1640 medium (10% FBS h.i.). After 24 hours primary ALL cells were thawed 
and seeded as suspension culture alone or in co-culture with MSCs at a number of 400,000 
cells per well in AIM-V medium. Three days later, ALL cells were collected from 
monoculture or co-culture by scraping and stained with 7-AAD (BD Pharmingen). Cell 
viability (7-AAD negative population) was measured by FACS using counting beads 
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(SPHERO Accu Count Blanc Particles, Spherotech Inc.) for cell counts normalization. 
Viabilities shown are average viabilities of duplicate wells (normalized to input) and 
standard deviations.
Cell cycle assay—MSCs were seeded in 96-well tissue culture plates at a concentration 
of 10,000 cells per well in 100 μL AIM-V medium. After 24 hours ALL cells were added at 
a concentration of 100,000 cells per well in 90 μL AIM-V. The Click-iTEdU Alexa Fluor 
488 Flow Cytometry Assay Kit (Life Technologies) in combination with propidium iodide 
was used to measure proliferation and to identify the different phases of the cell cycle on 
days 1 and 3. Co-cultured cells were incubated with EdU (10 μM) for 20 hours before cell 
cycle read-out with flow cytometry. The cell cycle assay was performed in triplicates and at 
least two independent experiments were performed for each sample. Similar variances were 
obtained between the groups that were statistically compared.
In vitro drug screening and automated microscopy—MSCs were seeded in 384-
well plates at a concentration of 2,500 cells per well in 30 μL AIM-V medium. After 24 
hours, ALL cells were added at a concentration of 25,000 to 30,000 cells per well in 27.5 μL 
AIM-V. Drugs were added as single agents after additional 24 hours using the pipetting 
robot epMotion 5070 (Eppendorf). Drug response was normalized to ALL cells treated with 
the drug vehicle alone. Experiments were performed in duplicates in five different dilutions 
(1, 10, 100, 1,000 and 10,000 nM). For two samples comparable results were obtained in 
two independent drug screening experiments. After 72 or 96 hours of drug incubation, cells 
were stained using the CyQUANT direct cell proliferation assay (Life technologies). 20 μL 
staining mix (AIM V medium, CyQUANT (1:300), repressor (1:20)) was added into each 
well followed by an incubation time of 1 hour at 37°C, 5 % CO2. Subsequently, automated 
imaging was performed using the ImageXpress Micro microscope (Molecular Devices) 
equipped with a CoolSNAP HQ camera (Photometrics) and a 10x plan fluor objective with 
0.3 NA (Nikon). Nine images were taken per well, covering 50% of each well and captured 
employing the MetaXpress software (Molecular Devices). Images were processed using 
CellProfiler software (Broad Institute, Cambridge, MA). Cells were classified and counted 
using the Advanced Cell Classifier software. This software uses random forest classification 
to assign ALL cells properly.
Western blot—Whole cell extracts were prepared from 1 × 106 cells using 
radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-Cl pH 7.5, 150 mMNaCl, 1% 
NP-40, 1 mM EDTA pH 8.0, 0.1% SDS) supplemented with Complete mini protease 
inhibitor cocktail (Roche Life Science) for 20 minutes on ice, sonicated as necessary, and 
diluted with SDS loading buffer (250 mM Tris pH 6.8, 4% SDS, 0.02% bromophenol blue, 
40% glycerol, 4% (v/v) β-mercaptoethanol). After SDS-PAGE, proteins were blotted onto 
nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk and incubated 
with primary Bcl-2 (Clone 124; Dako) and tubulin antibodies diluted 1:1,000 in milk. 
Horseradish peroxidase-labeled anti-mouse antibodies were used for signal detection with 
chemiluminescence substrate and direct scanning.
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In vivo experiments—ALL cells were recovered from cryopreserved xenograft samples, 
and per thawed sample 12 to 16 mice were transplanted with 1,000,000 cells per mouse. 
After three days, randomized cohorts were treated with 100 mg/kg of ABT-199 (ABBVIE) 
or vehicle control with 6 to 8 mice per treatment arm85. ABT-199 or vehicle control were 
administered orally daily for two weeks. Mice of the ABT-199 group transplanted with 
sample 7a were additionally treated with a second block (100 mg/kg of ABT-199 for 14 
days) starting at day 66, when the frequency of circulating leukemia cells started to increase 
again. Follow-up of circulating leukemia cells was performed every seven days by flow 
cytometry with rat anti-mouse CD45, mouse anti-human CD45, and mouse anti-human 
CD19; frequency of leukemia cells as ratio of mCD45-hCD45+ hCD19+ count to total 
lymphocytes. The investigator was blinded to the group allocation during the assessment of 
outcome. To evaluate the ability of ABT-199 to decrease tumor burden, four mice in the 
control group were treated when the frequency of leukemia cells in the peripheral blood was 
equal or higher than 50%. Follow-up of circulating leukemia cells was performed every four 
to seven days. In vivo experiments were terminated when the frequency of circulating 
leukemia cells reached 50% or earlier if the mice showed abnormal behavior. One in vivo 
experiment was performed per each sample.
Statistical analysis
Differences in the distribution of categorical variables among patient subsets were analyzed 
using Fisher’s exact or chi-squared test. Comparisons of continuous variables between 
groups were performed by t-test or Mann-Whitney U test.
Drug responses were evaluated by fitting DMSO-normalized response data with the four-
parameter log-logistic function of the form:
as implemented in the drc package of R (version 2.3-96). Outliers were detected and 
removed prior to curve-fitting using Bayesian change point analysis25 (R package bcp, 
version 3.0.1). Non-convergent cases (e.g., drugs with no activity) were identified based on 
linear fit parameters. Hierarchical clustering was performed to group patients according to 
their drug-response profiles (R package gplots version 2.14.2). Drugs with differential 
activity in patients with TCF3-PBX1- compared to TCF3-HLF-positive ALL were identified 
using a t-test (p-value <= 0.05). In in vivo experiments, 25% of circulating leukemia cells or 
termination of the experiment if 25% of leukemia was not reached were considered as an 
event in the Kaplan-Meier analysis. For sample 9a, 50% was used because of the rapid 
engraftment. Differences in the survival of mice receiving ABT-199 or vehicle control were 
determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genetic lesions identified in pediatric TCF3-HLF- and TCF3-PBX1-positive ALL
(a) Breakpoints in TCF3, PBX1 and HLF cluster in genomic hotspot regions. Boxes 
correspond to exonic regions; arcs represent fusions in patient samples. (b) TCF3 
breakpoints cluster in two TCF3 intronic regions: between exons 16 and 17 (type 1) and 
between exons 15 and 16 (type 2). On the transcript level, type 1 translocations join TCF3 
exon 16 to HLF exon 4, including inserted non-template and intronic sequences and new 
splice acceptor sites (patients 8 and 9). Type 2 translocations occur downstream of exon 15 
and exclude TCF3 exon 16 from the fusion transcript (patients 6, 7 and 11). (c) Absence of 
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overlapping somatic structural and nucleotide variations between the cohorts. TCF3-HLF-
positive ALL is characterized by mutually exclusive PAX5, BTG1 and VPREB1 deletions 
and nonsynonymous nucleotide variations in TCF3 (p.Asp561Val, “D561V” in patient 8 and 
p.Ser467Gly in patient 13 of the validation cohort, the latter not included here). Subclonal 
RAS pathway mutations are exclusively detected in HLF-, but not in PBX1-fused cases. (d) 
Models of wild-type and mutant TCF3 based on the crystal structure of TCF3 in complex 
with the transcription factors SCL, LMO2 and LDB1 bound to DNA.58 Upon LMO2 
binding, bonds are formed between TCF3 and SCL, including a hydrogen bond (dashed line) 
between D561 and R230 reducing the DNA binding capacity of the complex. Inset: D561V 
introduces a hydrophobic valine residue close to polar residues that may interfere with 
hydrogen bonding, thus altering the DNA binding properties of the complex. (For details see 
Source file for Figure 1.)
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Figure 2. TCF3-HLF programs leukemia to a hybrid hematopoietic transcriptional state
(a) Heatmap of the 401 differentially expressed genes between the two ALL subtypes 
(edgeR, |log2(fold change)| ≥ 1, FDR ≤ 0.001). (b) Enriched hematopoietic stages in TCF3-
HLF-positive (orange) and TCF3-PBX1-positive (green) ALL. Stages shown include 
hematopoietic stem cells (HSC), common myeloid progenitors (CMP), lymphoid-specified 
progenitors (GMP and MEP), neutrophils (NEUTRO), monocytes (MONO), multilymphoid 
progenitor (MLP), early T cell precursors (ETP), pro-B cells (PROB), T cells (TCELL), and 
B cells (BCELL). Gene set enrichment analysis was carried out using Genomatix genome 
analyzer and Gene Set Enrichment Analysis (GSEA)59 (GSEA: FDR ≤ 0.02; genomatix 
genome analyzer: adjusted p-value ≤ 0.02). The source of the significant enriched gene sets 
is noted by the superscript: 1) curated gene sets of hematopoietic precursors31; 2) human 
immunologic gene signatures (MSigDB v4.0)32; 3) text mining-based tissue specific gene 
sets60. (c) Enrichment plot for the HSC signature31. (d) Components of the TCF3-HLF-
positive ALL signature reveal functional annotation related to stem cells and their cellular 
location (Genomatix genome analyzer: p-value = 4.65 × 10−4, adjusted p-value < 0.001). 
(For details see Source file for Figure 2.)
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Figure 3. The genomic landscape of TCF3-HLF- and TCF3-PBX1-positive ALL is preserved in 
patient-derived leukemia xenografts
(a) Xenografts were established from cryopreserved patient samples at diagnosis (samples 
“a”), at follow-up with minimal residual disease (MRD, <1 leukemic cell in 10,000 cells, 
samples “b”) or from disease progression (samples “c”) and subjected to whole exome and 
transcriptome sequencing as well as multiplex ligation-dependent probe amplification 
(MLPA). All available MRD samples from TCF3-HLF-positive cases were successfully 
engrafted. (b) Comparison of all transcriptionally expressed nucleotide variations and of 
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selected recurrent deletions frequently found in pediatric ALL in corresponding patient (P) 
and xenograft (X) samples. Deletions and nucleotide variations are colored according to 
their frequency in the analyzed leukemic cell population. Deletion frequencies were 
calculated by integrating whole genome and whole exome sequencing data with MLPA data. 
Nucleotide variation frequencies were calculated by integrating whole genome, whole 
exome and transcriptome sequencing data. (For details see Source file for Figure 3.)
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Figure 4. Major components of the gene expression signature of TCF3-HLF- and TCF3-PBX1-
positive ALL are conserved in patient-derived xenografts
Hierarchical clustering of primary and patient derived xenograft (PDX) ALL samples based 
on the expression of the 401 genes of the signature defined with primary samples (Fig. 2) 
shows that xenografts clearly group with their corresponding primary samples. (For details 
see Source file for Figure 4.)
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Figure 5. Drug activity profiling of TCF3-translocated leukemia reveals relevant differences in 
drug sensitivity
(a) Unsupervised clustering based on the drug activity profile of 98 compounds (logIC50) 
separates the two subtypes. Fitted values are provided in the supplementary section (absolute 
IC50). Numbers identify the compounds shown in (c). (b) Principal component analysis of 
the response variables IC50, EC50, EC90 and AUC (Supplementary Table 24) show TCF3-
PBX1-positive and TCF3-HLF-positive ALL in two distinct clusters. The separation of 
TCF3-PBX1-positive and TCF3-HLF-positive ALL is determined by responses to 
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topoisomerases, BCL2 inhibitors, glucocorticoids and antimitotic agents, which correlate 
with the first three principal components. (c) Selection of drugs based on differences in 
sensitivity or resistance in TCF3-PBX1-positives and TCF3-HLF-positives. For comparison, 
the corresponding drug activity is indicated for 25 additional ALL samples tested on the 
same platform, including standard risk (SR, n=5), medium risk (MR, n=4), and high risk 
(HR, n=16) cases (Supplementary Table 25). Boxplots extend from the first to the third 
quartiles (hinges) of the response range for each compound. Whiskers correspond to values 
from the hinge to the lowest or highest values within 1.5x of the distance between the first 
and third quartiles, respectively. Drugs with differential activity include docetaxel, 
paclitaxel, vincristine, AT9283, barasertib, BI2536, torin-1, dasatinib, lestaurtinib and 
XL228 (p≤0.05). Drugs which are active across the patients include doxorubicin, idarubicin, 
mitoxantrone, bortezomib, panobinostat, NVP-AUY922, ABT-199 (venetoclax) and 
navitoclax. (For details see Source file for Figure 5.)
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Figure 6. The BCL2 antagonist ABT-199 (venetoclax) shows promising anti-leukemic activity in 
TCF3-HLF-positive xenografts
(a) In vitro dose response curves normalized against DMSO treated controls. (b) Merged 
absolute RPKM values of xenografts derived from the same primary leukemia sample 
(upper panel) and western blot for BCL2 (lower panel) in patient-derived xenografts as 
indicated. (c,d) In vivo response to ABT-199 on TCF3-HLF-positive xenografts. Treatment 
(grey bar) with 100 mg kg-1 qd ABT-199 (magenta) or with vehicle control (turquoise) were 
administered orally for 14 days (6-8 mice per treatment arm). Two treatment courses were 
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administrated to xenograft 7a. For survival analysis an event was defined when at least 25% 
of leukemic cells were detected by FACS (mCD45−hCD19+hCD45+) in the peripheral 
blood. Differences in the survival of mice receiving ABT-199 or vehicle control were 
determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test.
(e) Mice from the control arm of (c,d) were treated with ABT-199 when more than 50% of 
ALL cells were detected in the blood. Mean and SD are shown (n=4). (For details see 
Source file for Figure 6.)
Fischer et al. Page 31
Nat Genet. Author manuscript; available in PMC 2016 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
